Positive Phase IIa stroke clinical data for ReNeuron's CTX

Shares of UK-based ReNeuron Group (AIM: RENE) rose as much as 4% in early trading, as the company announced the publication in a peer reviewed journal of positive clinical data from the PISCES II Phase IIa clinical trial of its CTX stem cell therapy candidate for disability resulting from stroke.

Data from the PISCES II clinical trial have been published online in the Journal of Neurology, Neurosurgery, and Psychiatry in a paper titled Intracerebral implantation of human neural stem cells and motor recovery after stroke: multicentre prospective single-arm study (PISCES-2)”, Keith Muir et al.  http://jnnp.bmj.com/cgi/content/full/jnnp-2019-322515

PISCES II was a single arm, open-label study in patients living with significant disability resulting from ischaemic stroke. A total of 23 stable stroke patients with moderate to severe disability were treated with a single dose of 20 million CTX cells a median of seven months post-stroke.  Clinically-meaningful improvements in disability scales were measured out to 12 months post-implantation.